MA35458B1 - Variants du facteur de croissance des fibroblastes 21 - Google Patents

Variants du facteur de croissance des fibroblastes 21

Info

Publication number
MA35458B1
MA35458B1 MA36861A MA36861A MA35458B1 MA 35458 B1 MA35458 B1 MA 35458B1 MA 36861 A MA36861 A MA 36861A MA 36861 A MA36861 A MA 36861A MA 35458 B1 MA35458 B1 MA 35458B1
Authority
MA
Morocco
Prior art keywords
variants
growth factor
fibroblast growth
fgf21
dyslipidemia
Prior art date
Application number
MA36861A
Other languages
English (en)
Inventor
Craig Duane Dickinson
David Albert Driver
Ryan James Darling
Malgorzata Donata Gonciarz
Radmila Micanovic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35458(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA35458B1 publication Critical patent/MA35458B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des variants pharmacologiquement puissants et/ou stables du facteur de croissance 21 du fibroblaste humain (fgf21), des compositions pharmaceutiques comprenant des variants fgf21, ainsi que des procédés de traitement du diabète de type 2, l'obésité, la dyslipidémie, ou le syndrome métabolique, ou toute combinaison de ceux-ci, utilisant de tels variants.
MA36861A 2011-10-04 2014-03-27 Variants du facteur de croissance des fibroblastes 21 MA35458B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04
PCT/US2012/057053 WO2013052311A1 (fr) 2011-10-04 2012-09-25 Variants du facteur de croissance 21 du fibroblaste

Publications (1)

Publication Number Publication Date
MA35458B1 true MA35458B1 (fr) 2014-09-01

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36861A MA35458B1 (fr) 2011-10-04 2014-03-27 Variants du facteur de croissance des fibroblastes 21

Country Status (28)

Country Link
US (2) US8541369B2 (fr)
EP (1) EP2763689B1 (fr)
JP (1) JP6060167B2 (fr)
KR (1) KR20140059271A (fr)
CN (1) CN103906530B (fr)
AP (1) AP2014007532A0 (fr)
AR (1) AR087973A1 (fr)
AU (1) AU2012318956A1 (fr)
BR (1) BR112014007532A2 (fr)
CA (1) CA2843520A1 (fr)
CL (1) CL2014000801A1 (fr)
CO (1) CO6910165A2 (fr)
CR (1) CR20140142A (fr)
DO (1) DOP2014000050A (fr)
EA (1) EA201490521A1 (fr)
EC (1) ECSP14013285A (fr)
ES (1) ES2548214T3 (fr)
IL (1) IL230754A0 (fr)
IN (1) IN2014CN00782A (fr)
MA (1) MA35458B1 (fr)
MX (1) MX2014004159A (fr)
PE (1) PE20142044A1 (fr)
PH (1) PH12014500740A1 (fr)
SG (1) SG11201401792UA (fr)
TN (1) TN2014000096A1 (fr)
TW (1) TWI461435B (fr)
WO (1) WO2013052311A1 (fr)
ZA (1) ZA201400882B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2013006486A2 (fr) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, utilisations et procédés pour le traitement de troubles et de maladies métaboliques
CA2869320A1 (fr) * 2012-05-15 2013-11-21 Eli Lilly And Company Usages therapeutiques de proteines de variant du facteur 21 de croissance des fibroblastes en vue d'accroitre la formation osseuse ou les depots
CN104364261B (zh) 2012-06-11 2017-04-05 伊莱利利公司 成纤维细胞生长因子21变体
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
WO2014085365A2 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
EP3125921B1 (fr) * 2014-03-11 2020-07-08 Novartis AG Variants de fgf21 pour l'utilisation dans le traitement de la lipodystrophie partielle indue par arv/sida
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
WO2016065106A1 (fr) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
WO2016073855A1 (fr) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (fr) * 2016-06-22 2017-12-28 Novo Nordisk A/S Compositions pharmaceutiques de dérivés de fgf21 et leurs utilisations
WO2018039557A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
ES3014984T3 (en) 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
EP3678686A1 (fr) 2017-09-08 2020-07-15 Bristol-Myers Squibb Company Facteur de croissance des fibroblastes 21 (fgf-21) modifié destiné à une utilisation dans des méthodes de traitement de la stéatohépatite non alcoolique (nash)
CN111601613A (zh) 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
EP3935075A4 (fr) 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. Molécule polypeptidique et son application
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
KR20220125289A (ko) 2020-01-08 2022-09-14 브리스톨-마이어스 스큅 컴퍼니 Fgf-21 접합체 제제
WO2021139744A1 (fr) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugués de protéines de fusion du glp-1 et du fgf21
WO2022032187A1 (fr) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
KR20240034235A (ko) 2021-07-14 2024-03-13 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 대사 장애를 위한 융합 폴리펩타이드

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
AU2004303783A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
DK1789442T3 (da) * 2004-09-02 2009-11-16 Lilly Co Eli Muteiner af fibroblastvækstfaktor 21
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
MX2010013333A (es) * 2008-06-04 2011-04-05 Amgen Inc Mutantes fgf21 y usos de los mismos.
WO2010065439A1 (fr) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants de facteurde croissance 21 du fibroblaste
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof

Also Published As

Publication number Publication date
CL2014000801A1 (es) 2014-09-12
CA2843520A1 (fr) 2013-04-11
DOP2014000050A (es) 2014-04-15
EP2763689B1 (fr) 2015-08-12
ES2548214T3 (es) 2015-10-14
TW201326198A (zh) 2013-07-01
ZA201400882B (en) 2016-02-24
US8883726B2 (en) 2014-11-11
JP2014530220A (ja) 2014-11-17
TN2014000096A1 (en) 2015-07-01
CO6910165A2 (es) 2014-03-31
PE20142044A1 (es) 2014-12-06
KR20140059271A (ko) 2014-05-15
CN103906530B (zh) 2016-01-20
ECSP14013285A (es) 2014-05-31
IL230754A0 (en) 2014-03-31
TWI461435B (zh) 2014-11-21
MX2014004159A (es) 2015-02-12
JP6060167B2 (ja) 2017-01-11
US20130324460A1 (en) 2013-12-05
WO2013052311A1 (fr) 2013-04-11
CN103906530A (zh) 2014-07-02
IN2014CN00782A (fr) 2015-04-03
AP2014007532A0 (en) 2014-03-31
EA201490521A1 (ru) 2014-07-30
BR112014007532A2 (pt) 2017-04-04
CR20140142A (es) 2014-05-02
US20130085098A1 (en) 2013-04-04
US8541369B2 (en) 2013-09-24
PH12014500740A1 (en) 2020-10-19
EP2763689A1 (fr) 2014-08-13
SG11201401792UA (en) 2014-08-28
AU2012318956A1 (en) 2014-02-06
AR087973A1 (es) 2014-04-30

Similar Documents

Publication Publication Date Title
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
UA104626C2 (ru) Анти-vegf антитело и его применение
EA201270480A1 (ru) Новые соединения
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3